EBS - Emergent Biosolutions Inc logo

Emergent Biosolutions Inc

EBS

Emergent BioSolutions Inc. develops and manufactures vaccines and antibody therapeutics for public health threats, including smallpox and anthrax. It also offers emergency opioid overdose treatments and contract development services to healthcare providers.

โš•๏ธ Healthcare NYSE Listed 2006 $ USD
$1,000 invested 20 years ago โ†’$530today

Score Overview

1 Year
Score
Net Growth-4x
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-12.63%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score2.0
Net Growth-218.77%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth-63.40%
Rev TrendNever
Revenue Consistencyโ€”
10 Years
Score
Net Growth-5x
Net Trend40%
Net Income Consistency
Rev Growth32.79%
Rev Trend50%
Revenue Consistency
20 Years
Score4.0
Net Growth-11x
Net Trend55%
Net Income Consistency
Rev Growth324.99%
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth-11x
Net Trend55%
Net Income Consistency
Rev Growth324.99%
Rev Trend60%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Emergent Biosolutions Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • EBS

2017: 21.7% ยท 2021: 15.1% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-11-17
$ 5.61โ€”
1 Year2025-11-17
$ 10.10-44.46%
5 Years2021-11-17
$ 40.90-86.28%
10 Years2016-11-17
$ 29.86-81.21%
20 Years2006-11-17
$ 10.58-46.96%
All Time2006-11-15
$ 11.05-49.23%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 649M-$ 260M$ 175M
2025$ 742M$ 52M$ 205M
2024$ 1.04B-$ 190M$ 99M
2023$ 1.04B-$ 760M$ 111M
2022$ 1.11B-$ 211M$ 642M
2021$ 1.77B$ 219M$ 576M
2020$ 1.57B$ 305M$ 621M
2019$ 1.10B$ 54M$ 168M
2018$ 782M$ 62M$ 112M
2017$ 560M$ 82M$ 178M
2016$ 488M$ 51M$ 271M
2015$ 489M$ 62M$ 312M
2014$ 404M$ 36M$ 280M
2013$ 312M$ 31M$ 179M
2012$ 281M$ 23M$ 141M
2011$ 273M$ 23M$ 145M
2010$ 286M$ 51M$ 171M
2009$ 234M$ 31M$ 102M
2008$ 178M$ 20M$ 91M
2007$ 182M$ 22M$ 105M
IPO2006$ 152M$ 22M$ 76M
EBS - Emergent Biosolutions Inc logo

Emergent Biosolutions Inc fundamental performance

Between 2015 and 2025, revenue grew from $ 489M to $ 742M and net income declined from $ 62M to $ 52M. Revenue increased in 5 of those 10 years; net income in 4.

Across Emergent Biosolutions Inc's full reported history, from 2006 to 2025, revenue grew from $ 152M to $ 742M and net income grew from $ 22M to $ 52M. Revenue increased in 60% of the years measured; net income in 55%.

Emergent Biosolutions Inc currently holds a 20-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.

Membership

Continue EBSโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,187 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$149 / year

or $19/month

Continue with Membership

30-day money-back guarantee.

Explore other companies